Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinson's Disease: Potential Implications in Cognitive Dysfunction and Dementia?

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|17|28|3253-3261

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.17, Iss.28, 2010-09, pp. : 3253-3261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 11, Iss. 4, 2011-12 ,pp. : 305-320

Bentham Science Publishers

Access to resources Recommend Favorite

Cognitive Impairment and Dementia in Patients with Parkinson Disease

By  

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 10, 2009-07 ,pp. : 903-912

Bentham Science Publishers

Access to resources Recommend Favorite

L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?

By  

Letters in Drug Design & Discovery, Vol. 2, Iss. 7, 2005-11 ,pp. : 558-562

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Dopamine in Learning and Memory: Implications for the Treatment of Cognitive Dysfunction in Patients With Parkinson's Disease

By Kulisevsky J.  

Drugs & Aging, Vol. 16, Iss. 5, 2000-05 ,pp. : 365-379

Adis International

Access to resources Recommend Favorite

Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic?

By Lane Emma   Dunnett Stephen  

Psychopharmacology, Vol. 199, Iss. 3, 2008-08 ,pp. : 303-312

Springer Publishing Company

Access to resources Recommend Favorite